# Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

> **NCT01952574** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 483 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Erenumab
- **DRUG:** Placebo
- **DRUG:** Erenumab PFS
- **DRUG:** Erenumab AI/Pen

## Key facts

- **NCT ID:** NCT01952574
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-06
- **Primary completion:** 2014-09-25
- **Final completion:** 2019-11-12
- **Target enrollment:** 483 (ACTUAL)
- **Last updated:** 2022-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01952574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01952574, "Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01952574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*